Kura Oncology Quarterly Balance Sheet
NASDAQ: KURAHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Kura Oncology financial position
As of Jun 30, 2026, Kura Oncology reported total assets of $587.8 million, down 13.9% from a year earlier against total liabilities of $539.4 million. Shareholders' equity stood at $48.4 million, or 8.2% of assets. The company held $70.2 million in cash and equivalents against $9.8 million of debt, a net cash position of $60.5 million.
The current ratio (current assets divided by current liabilities) was 4.73, meaning short-term assets cover obligations due within a year. Debt-to-equity was 0.20.
Summary generated from market data by MetaCap's automated system. Methodology
Kura Oncology balance sheet (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | 70.24M | 39.08M | 149.10M | 95.29M | 81.95M | 51.27M | 224.46M | 49.48M | 45.18M | 41.51M | 37.32M | 28.74M |
| Short-Term Investments | 448.78M | 541.74M | 518.14M | 454.38M | 548.78M | 606.92M | 502.93M | 405.82M | 446.34M | 485.62M | 386.64M | 423.85M |
| Receivables | 9.45M | 9.35M | 8.80M | 35.94M | 4.57M | 48.75M | 2.06M | — | — | — | — | — |
| Inventory | 2.48M | 843.00K | 413.00K | — | — | — | 0 | — | — | — | — | — |
| Total Current Assets | 559.44M | 623.78M | 708.66M | 620.66M | 660.08M | 724.20M | 744.83M | 463.19M | 499.77M | 537.84M | 432.48M | 459.92M |
| Property, Plant & Equipment | 7.59M | 7.61M | 7.86M | 7.40M | 3.91M | 2.35M | 1.68M | 1.31M | 1.52M | 1.71M | 1.86M | 2.06M |
| Total Assets | 587.79M | 652.55M | 738.36M | 649.38M | 682.42M | 743.76M | 760.16M | 478.84M | 515.12M | 553.91M | 448.94M | 473.77M |
| Accounts Payable | 2.39M | 7.04M | 5.02M | 4.67M | 1.70M | 4.61M | 1.47M | 3.01M | 2.06M | 7.53M | 2.30M | 1.76M |
| Short-Term Debt | 4.22M | — | 0 | 4.34M | 3.11M | 1.92M | 2.61M | 1.72M | 847.00K | — | — | — |
| Total Current Liabilities | 118.19M | 101.50M | 116.97M | 121.30M | 107.17M | 89.77M | 78.71M | 40.37M | 33.45M | 32.27M | 35.26M | 27.52M |
| Long-Term Debt | 5.57M | 9.75M | 9.71M | 5.34M | 6.51M | 7.65M | 6.92M | 7.76M | 8.58M | 9.38M | 9.33M | 9.29M |
| Total Liabilities | 539.36M | 544.67M | 564.23M | 406.84M | 376.94M | 379.36M | 346.52M | 55.07M | 49.05M | 48.82M | 51.66M | 43.83M |
| Shareholders' Equity | 48.43M | 107.88M | 174.13M | 242.54M | 305.49M | 364.41M | 413.64M | 423.77M | 466.07M | 505.08M | 397.27M | 429.94M |
| Retained Earnings | -1.32B | -1.25B | -1.17B | -1.09B | -1.02B | -952.85M | -895.42M | -876.21M | -821.80M | -770.96M | -721.44M | -678.65M |
| Total Debt | 9.79M | 9.75M | 9.71M | 9.67M | 9.62M | 9.57M | 9.52M | 9.47M | 9.42M | 9.38M | 9.33M | 9.29M |
| Net Cash (Debt) | 509.24M | 571.07M | 657.53M | 539.99M | 621.11M | 648.62M | 717.87M | 445.82M | 482.10M | 517.75M | 414.63M | 443.30M |
| Shares Outstanding | 88.95M | 88.76M | 87.86M | 87.02M | 86.80M | 80.78M | 78.23M | 77.75M | 76.42M | 76.18M | 74.35M | 74.25M |
This table shows 12 quarterly periods of Kura Oncology's balance sheet, from Q2 2026 back to Q3 2023, across 17 line items including cash & equivalents, short-term investments, receivables. Values in USD; B = billions, M = millions. Fiscal periods follow KURA's reporting calendar. What is a balance sheet?